IL6 and systemic-onset juvenile idiopathic arthritis: In the cytokine storm or MAS states, including those linked to chimeric antigen receptor T-cell therapy (CAR-T) or Still’s disease, impressive responses have been reported with anti-cytokine therapy against interleukin 6 (IL-6) or interleukin 1 (IL-1) [8,9].